A Prodrug That Inhibits Angiogenesis
  • William D. Figg
  • Eddie Reed
  • Shawn Green
  • James M. Pluda
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Thalidomide (N-phthalidoglutamide, C13 O4 N2 H9, mol wt = 258.23) (Fig. 1) is a glutamic acid derivative [S(-) and R(+) racemate] (1) that was first described in 1953 by the Swiss pharmaceutical company Ciba. Ciba discontinued research on the compound and a German company Chemie Grunenthal undertook development in 1954. It was later marketed as a sleeping pill, and was subsequently blamed for nearly 12,000 birth defects between the late 1950s and early 1960s (2).


Teratogenic Effect Glutaric Acid Antiangiogenic Activity Lepromatous Leprosy Thalidomide Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fabro, S., Smith, R. L., and Williams, R. T. (1967) Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215(98), 296.PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous (1990) Medical news and perspectives: Thalidomide’s back in the news, but in more favorable circumstances. JAMA 263, 1467,1468.Google Scholar
  3. 3.
    Schumacher, H., Smith, R. L., and Williams, R. T. (1965) The metabolism of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338–351.Google Scholar
  4. 4.
    Simmons, B. R., Lush, R. M., and Figg, W. D. (1965) A reverse-phase HPLC method using solid phase extraction for quantitating thalidomide. Anal. Chim. Acta 339, 91–97.CrossRefGoogle Scholar
  5. 5.
    Bauer, K. S., Dixon, S. C., and Figg, W. D. (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem. Pharmacol. 55, 1827–1834.PubMedCrossRefGoogle Scholar
  6. 6.
    D’Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082–4085.Google Scholar
  7. 7.
    Masiero, L., Figg, W. D., and Kohn, E. C. (1997) new anti-angiogenesis agents: review of experience with CAI, thalidomide, TNP-470, and IL-12. Angiogen. J. 1, 23–35.CrossRefGoogle Scholar
  8. 8.
    Frances, O. K. (1997) Historical perspective, in Conference Thalidomide: Potential Benefits and Risks. National Institutes of Health, Bethesda, MD.Google Scholar
  9. 9.
    McBride, W. G. (1968) Thalidomide and congenital abnormalities. Lancet 2, 1358.Google Scholar
  10. 10a.
    Butler, H. (1977) Effect of thalidomide on a prosimian: greater galago (Galago crassicaudatus). J. Med. Primato. 6, 319–324.Google Scholar
  11. 10.
    b.Cahen, R. L. (1966) Experimental and clinical chemoteratogenesis. Adv. Pharmacol. 4, 263–349.CrossRefGoogle Scholar
  12. 10c.
    Figg, W. D., Bergan, R., Brawley, O., Tompkins, A., Lineham, M., Duray, P., Bauer, K. S., Pluda, J., and Reed, E. (1997) Randomized phase II study of thalidomide in androgen independent prostate cancer. Proc. Am. Soc. Clin. Oncol. 16, 1189.Google Scholar
  13. 11.
    Fabro, S. and Smith, R. L. (1966) Teratogenic activity of thalidomide in the rabbit. J. Pathol. Bacteriol. 91,511–519.PubMedCrossRefGoogle Scholar
  14. 12.
    Giroud, A., Tuchmann-Duplessis, H., and Mercier-Parot, L. Congential maliformation produced in the mouse after administration of weak dose of thalidomide. CR Hebd. Acad. Sci. Ser. D. Google Scholar
  15. 13.
    Stephens, T. D. (1988) Proposed mechanisms of action in thalidomide embryopathy. Teratology 38(3), 229–239.PubMedCrossRefGoogle Scholar
  16. 14.
    Corral, L., Muller, G. W., Moreria, A. L., Chen, Y., Wu, M., Stirling, D., and Kaplan, G. (1996) Selection of novel analogs of thalidomide with enhanced tumor necrosis factor inhibitory activity. Mol. Med. 2, 506–515.PubMedGoogle Scholar
  17. 15.
    Kenyon, B. M., Browne, F., and D’Amato, R. J. (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64, 971–978.PubMedCrossRefGoogle Scholar
  18. 16.
    Fabro, S., Smith, R. L., and Williams, R. T. (1967) The fate of the hydrolysis products of thalidomide in the pregnant rabbit. Biochem. J. 104(2), 570–574.PubMedGoogle Scholar
  19. 17.
    Braun, A. G. and Weinreb, S. L. (1985) Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. Tera. Carcin. Mutagen. 5(3), 149–158.CrossRefGoogle Scholar
  20. 18.
    Braun, A. G., Harding, F. A., and Weinreb, S. L. (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome p450. Toxicol. Appl. Pharmacol. 82(1), 175–179.PubMedCrossRefGoogle Scholar
  21. 19.
    Brode, E. (1968) Experimental studies with cyclicimides. Modification of hypohyseal-adrenal axis by thalidomide. Arzneimittelforschung 18(6), 661–665.PubMedGoogle Scholar
  22. 20.
    Piscitelli, S. C., Figg, W. D., Hahn, B., Kelly, G., Thomas, S., and Walker, R. E. (1997) Single dose pharmacokinetics of thalidomide in HIV-infected patients. Antimicrob. Agents Chemother. 41, 2797–2799.PubMedGoogle Scholar
  23. 21.
    Figg, W. D., Raje, S., Bauer, K. S., Tompkins, A., Dyer, V., Davis, P., Venzon, D., Bergan, R., Chen, A., Hamilton, M., Pluda, J., and Reed, E. Pharmacokinetics of thalidomide in an elderly prostate cancer population. In review.Google Scholar
  24. 22.
    D’Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082–4085.PubMedCrossRefGoogle Scholar
  25. 23.
    Gordon, G. B., Spielberg, S. P., Blake, D. A., and Balasurbramanian, V. (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA 78(4), 2545–2548.PubMedCrossRefGoogle Scholar
  26. 24.
    Eisen, T., Boshoff, C., Vaughan, M. M., Pyle, L., Smith, I. E., Johnston, S. R. D., Buncker, C., Kitchen, P., Rowe, A., and Gore, M. E. (1998) Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian, and breast cancer with thalidomide: a phase II study. Proc. ASCO. Google Scholar
  27. 25.
    Politi, P., Reboredo, G., Losso, M., Vujacich, C., Schwartsmann, G., and Lewi, D. (1998) Phase I trial of thalidomide in AIDS-related Kaposi sarcoma. Proc. ASCO.Google Scholar
  28. 26.
    Long, G., Vredenburgh, J., Rizzieri D. A., Greenberg, C., Smith, C., Petros, W., Gilbert, C., Blackwell, K., Peters, K., Coniglio, D., Affronti, M. L., Brady, C., and Chao, N. J. (1998) Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation in patients with metastatic breast cancer. Proc. ASCO. Google Scholar
  29. 27.
    Grabstald, H. and Golbey, R. (1965) Clinical experience with thalidomide in patients with cancer. Clin. Pharmacol. Ther. 6, 298–302.PubMedGoogle Scholar
  30. 28.
    Olson, K. B., Hall, T. C., Horton, J., Khung, C. L., and Hosley, H. F. (1965) Thalidomide (n-phthaloylglutamimide) in the treatment of advanced cancer. Clin. Pharmacol. Ther. 6, 292–297.PubMedGoogle Scholar
  31. 29.
    Swartz, G. S., Shah, J., Fogler, B., Papathanassiu, A., and Green, S. J. 2-Methyl-2-phthalimidino glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastasis. In review.Google Scholar
  32. 30.
    Brooks, P. C., Clark, R. A. F., and Cheresh, D. A. (1994) Requirements of vascular integrin for angiogenesis. Science 264, 569–571.PubMedCrossRefGoogle Scholar
  33. 31.
    Neubert, R., Hinz, N., Thiel, R., and Neubert, D. (1996) Down regulation of adhesion receptor on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58, 295–316.PubMedCrossRefGoogle Scholar
  34. 32.
    Ausprunk, D., Falterman, K., and Folkman, J. (1978) The sequence of events in the regression of corneal capillaries. Lab. Invest. 38, 284–294.PubMedGoogle Scholar
  35. 33.
    Minchinton, A. I., Fryer, K. H., Wendt, K. R., Clow, K. A., and Hayes, M. N. (1996) The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 7, 339–343.Google Scholar
  36. 34.
    Ching, L. M., Xu, Z. F., Gummer, B. H., Palmer, B. D., Joseph, W. R., and Bauguley, B. C. (1995) Effect of thalidomide on tumor necrosis factor production and anti-tumor activity induced by 5,6dimethylxanthenome-4-acetic acid. Br. J. Cancer 72, 339–343.PubMedCrossRefGoogle Scholar
  37. 35.
    Pearson, J. M. H.and Vedagiri, M. (1969) Treatment of moderately severe erythema nodosum leprosum with thalidomide—a double-blind controlled trial. Leprosy Rev. 40, 111–116.PubMedGoogle Scholar
  38. 36.
    Sheskin, J. and Convit, J. (1969) Results of a double blind study of the influence of thalidomide on the lepra reaction. Int. J. Leprosy 37, 135–146.Google Scholar
  39. 37.
    Waters, M. F. R. (1971) An internally controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Leprosy Rev. 42, 2642.Google Scholar
  40. 38.
    Kluken, N. and Wente, W. (1974) Indications for thalidomide therapy for leprosy. Int. J. Dermatol. 13, 20–25.PubMedCrossRefGoogle Scholar
  41. 39.
    Koch, H. P. (1985) Thalidomide and Congeners as anti-inflammatory agents, in Progress in Medicinal Chemistry, vol. 22 (Ellis et al., eds.), pp. 165–242.Google Scholar
  42. 40.
    Sheskin, J. (1978) Study with nine thalidomide derivatives in the lepra reaction. Int. J. Dermatol. 17, 82–84.PubMedCrossRefGoogle Scholar
  43. 41.
    Cornea, P., Vladutiu, A., and Marcovici, G. (1967) The immuno-suppressive effect of thalidomide in experimental tuberculosis in guinea pigs. Tubercle 48, 51–53.Google Scholar
  44. 42.
    Chavanet, P., Lefranc, T., Bonnin, A., Waldner, A., and Ponler, H. (1990) Unusual cause of pharyngeal ulcerations in AIDS. Lancet 336, 383, 384.Google Scholar
  45. 43.
    Ellenrieder, M., Frankus, E., and Kruepe, W. (1967) Immunosuppression durch cyclische Imide bei der Ratte. Klin. Wochenschr. 45, 1159,1160.Google Scholar
  46. 44.
    Field, E. O., Gibbs, J. E., Tucker, D. F., and Hellmann, K. (1966) Effect of thalidomide on the graft versus host reaction. Nature 211, 1308–1310.PubMedCrossRefGoogle Scholar
  47. 45.
    Vogelsang, G. B., Hess, A. D., Fnedman, K. L., and Santos, G. W. (1989) Therapy of chronic graft-vhost disease in a rat model. Blood 74, 507–511.Google Scholar
  48. 46.
    Vogelsang, G. B., Hess, A. D., Gordon, G., Brundrette, R., and Santos, G. W. (1987) Thalidomide induction of bone marrow transplantation tolerance. Transplant. Proc. 19, 2658–2661.PubMedGoogle Scholar
  49. 47.
    Vogelsang, G. B., Hess, A. D., Gordon, G., and Santos, G. W. (1986) Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 41, 645–647.CrossRefGoogle Scholar
  50. 48.
    Vogelsang, G. B., Hess, A. D., and Santos, G. W. (1988) Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant. 3, 393–398.PubMedGoogle Scholar
  51. 49.
    Vogelsang, G. B., Tavlor, S., Gordon, G., and Hess, A. D. (1986) Thalidomide, a potent agent for the treatment of graft-versus-host disease. Transplant. Proc. 18, 904–906.Google Scholar
  52. 50.
    Vogelsang, G. B., Wells, M. C., Santos, G. W., Chen, T. L., and Hess, A. D. (1988) Combination lowdose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant. Proc. 20, 226–228.PubMedGoogle Scholar
  53. 51.
    Vogelsang, G. B., Farmer, E. R., Hess, A. D., et al. (1992) Thalidomide for the treatment of chronic graftversus host disease. N. Engl. J. Med. 326, 1055–1058.PubMedCrossRefGoogle Scholar
  54. 52.
    Barrett, A. J. (1987) Graft-versus-host disease: a review. J. Roy. Soc. Med. 80, 368–373.PubMedGoogle Scholar
  55. 53.
    Ferrara, J. L. M. and Deeg, H. J. (1991) Graft-versus-host disease. N. Engl. J. Med. 324, 667–671.PubMedCrossRefGoogle Scholar
  56. 54.
    Korngold, R. and Sprent, J. (1987) T-cell subsets and graft-versus-host disease. Transplantation 44, 335–339.PubMedCrossRefGoogle Scholar
  57. 55.
    Reinherz, E. L., Parkman, R., Rappeport, J., Rosen, F. S., and Schlossman, S. F. (1979) Aberrations of suppressor T cells in human graft-versus-host disease. N. Engl. J. Med. 300, 1061–1068.PubMedCrossRefGoogle Scholar
  58. 56.
    Wood, P. M. and Proctor, S. J. (1990) The potential use of thalidomide in the therapy of graft-versushost disease—a review of clinical and laboratory information. Leuk. Res. 14(5), 395–399.PubMedCrossRefGoogle Scholar
  59. 57.
    Chen, T. L., Vogelsang, G. B., Petty, B. G., Brundrett, R. B., Noe, D. A., et al. (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metabol. Dispos. 17, 402–405.Google Scholar
  60. 58.
    Vogelsang, G. B., Farmer, E. R., Hess, A. D., et al. (1992) Thalidomide for the treatment of chronic graftversus host disease. N. Engl. J. Med. 326, 1055–1058.PubMedCrossRefGoogle Scholar
  61. 59.
    Bemardo, P., Arrizabalaga, J., Iribarren, J. A., and Garde, C. (1990) Efiicacia de la talidomida en las ulceras esofagicas inespecificas en pacientes con sindrome de inmunodeficiencia adquirida. Med. Clin. 94, 48,49.Google Scholar
  62. 60.
    Bowers, P. W. and Powell, R. J. (1983) Effect of thalidomide on orogenital ulceration. Br. Med. J. 287, 799, 800.Google Scholar
  63. 61.
    Connolly, G. M., Hawkins, D., Harcourt-Webster, J. N., Parsons, P. A., Husain, O. A. N., et al. (1989) Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodefiiciency syndrome. Gut. 30, 1033–1039.PubMedCrossRefGoogle Scholar
  64. 62.
    Georghiou, P. R. and Kemp, R. J. (1990) HiV-associated oesophageal ulcers treated with thalidomide. Med. J. Aust. 152, 382,383.Google Scholar
  65. 63.
    Gorin, I., Vilette, B., Gehanno, P., and Escande, J. P. (1990) Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet 335, 1343.PubMedCrossRefGoogle Scholar
  66. 64.
    Radeff, B., Kuffer, R., and Samson, J. (1990) Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successtul treatment with thalidomide. J. Am. Acad. Dermatol. 23, 523–525.PubMedCrossRefGoogle Scholar
  67. 65.
    Gutierrez-Rodriguez, O., Starusta-Bacal, P., and Gutierrez-Montes, O. (1989) Treatment of refractory rheumatoid arthritis-the thalidomide experience. J. Rheumatol. 16, 158–163.PubMedGoogle Scholar
  68. 66.
    Johnke, H. and Zachariae, H. (1993) Thalidomide treatment ofprurigo nodularis. UgeskrLaeger 155(38), 3028–3030.PubMedGoogle Scholar
  69. 67.
    Knop, J., Bonsmann, G., Happle, R., Ludolph, A., Matz, D. R., et al. (1983)Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br. J. Dermatol. 108, 461–466.PubMedCrossRefGoogle Scholar
  70. 68.
    Ochonisky, S., Verroust, J., Bastuju-Garin, S., Cherardi, R., and Revus, J. (1994) Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch. Dermatol. 130(1), 66–69.PubMedCrossRefGoogle Scholar
  71. 69.
    Fullerton, P. M. and O’Sullivan, D. J. (1968) Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J. Neuro. Neurosurg. Psych. 31(6), 543–551.CrossRefGoogle Scholar
  72. 70.
    Wulff, C. H., Hoyer, H., Asboe-Hansen, G., and Brodthagen, H. (1985) Development ofpolyneuropahty during thalidomide therapy. Br. J. Dermatol. 112(4), 475–480.PubMedCrossRefGoogle Scholar
  73. 71.
    Hess, C. W., Hunziker, T., Kupfer, A., and Ludin, H. P. (1986) Thalidomide-induced peripheral neuropathy. A prospective clinical, nerophysiological and pharmacogenetic evaluation. J. Neurol. 223(2), 83–89.CrossRefGoogle Scholar
  74. 72.
    Hafstrom, T. (1967) Polyneuropathy after neurosedyn (thalidomide and its prognosis. Acta Neurol. Scand. 43(Suppl. 32), 1–41.Google Scholar
  75. 73.
    Chapon, F., Lechevalier, B., Da Silva, D. C., Rivrain, Y., Dupuy, B., et al. (1985) Neuropathies a la thalidomide. Rev. Neurolog. 141, 719–728.Google Scholar
  76. 74.
    Clemmensen, O. J., Olsen, P. Z., and Andersen, K. E. (1984) Thalidomide neurotoxicity. Arch. Dermatol. 120, 338–341.PubMedCrossRefGoogle Scholar
  77. 75.
    Gutierrez-Rodriguez, O., Starusta-Bacal, P., and Gutierrez-Montes, O. (1988) Thalidomide-induced neuropathy in rheumatoid arthritis patients. Arth. Rheum. 31, 145–146.CrossRefGoogle Scholar
  78. 76.
    Crawford, C. L. (1996) Thalidomide neuropathy. Nat. Med. 2, 132.PubMedCrossRefGoogle Scholar
  79. 77.
    Sheehen, N. J. Thalidomide neurotoxicity and rheumatoid arthritis.Google Scholar
  80. 78.
    Aronson, I. K., Yu, R., West, D. P., Van Den Broek, H., and Antel, J. (1984) Thalidomide-induced peripheral neuropathy. Arch. Dermatol. 120, 1466–1470.PubMedCrossRefGoogle Scholar
  81. 79.
    Schroder, J. M., Sellhous, B., Wohrmann, T., Kogel, B., and Zwingenberger, K. (1995) Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration. Acta Neuropathol. 89, 415–419.PubMedCrossRefGoogle Scholar
  82. 80.
    Hoyer, H., Wulff, C. H., Asboe-Hansen, G., and Brodthagen, H. (1983) Behandling afprurigo nodulans Hyde med talidomid. Ugeskrift Laeger 145, 3243–3245.Google Scholar
  83. 81.
    Sheskin, J. and Yaar, I. (1979) Motor-conduction velocity of cubital nerves in patients with leprosy reactions. Summary of a 13-year observation series during thalidomide therapy. Hautarzt 30(7), 376–379.PubMedGoogle Scholar
  84. 82.
    Locker, D., Superstine, E., and Sulman, F. G. (1971) The metabolism of the push and pull principle. Endocrine effects of thalidomide and its analogues. Arch. Int. Pharmacodyn. Ther. 194(1), 39–55.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • William D. Figg
  • Eddie Reed
  • Shawn Green
  • James M. Pluda

There are no affiliations available

Personalised recommendations